Structural biology and diabetes mellitus: molecular pathogenesis and rational drug design.
Emerging concepts in the aetiology and pathogenesis of Type 1 (insulin-dependent) diabetes mellitus may offer new opportunities for treatment and cure. Here we describe recent advances in structural molecular biology and molecular design relevant to rational drug discovery. Such approaches focus on the three-dimensional structures of macromolecules and their interactions. In the coming decade such techniques may be applied to a wide variety of diabetes-related targets.
Blundell
T
T
Department of Crystallography, Birkbeck College, University of London, UK.
Hubbard
R
R
Weiss
M A
MA
D000595:Amino Acid Sequence; D001665:Binding Sites; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology*; D015195:Drug Design; D006801:Humans; D007328:Insulin / Q000737:chemistry* / Q000627:therapeutic use*; D009682:Magnetic Resonance Spectroscopy; D008958:Models, Molecular; D008969:Molecular Sequence Data; D006005:Phosphorylases / Q000037:antagonists & inhibitors / Q000737:chemistry; D017433:Protein Structure, Secondary; D011994:Recombinant Proteins / Q000737:chemistry / Q000627:therapeutic use; D018139:Simplexvirus / Q000201:enzymology; D013937:Thymidine Kinase / Q000737:chemistry / Q000235:genetics; D014961:X-Ray Diffraction
D007328:Insulin; D011994:Recombinant Proteins; D006005:Phosphorylases; D013937:Thymidine Kinase